RB1 and neoplasm: For instance, in a whole-exome sequencing analysis of one or more tumor foci from 18 patients following 24 weeks of neoadjuvant leuprolide and abiraterone, Sowalsky et al31 identified enrichment of RB1 loss in residual disease.